Lulizumab_pegol

Lulizumab pegol

Lulizumab pegol

Add article description

Lulizumab pegol (INN;[1] development code BMS-931699) is a monoclonal antibody designed for the treatment of autoimmune diseases.[2]

Quick Facts Monoclonal antibody, Type ...

This drug was developed by Bristol-Myers Squibb.

References

  1. [1]
    World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
  2. [2]
    Statement On A Nonproprietary Name Adopted By The USAN Council - Lulizumab Pegol, American Medical Association.
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Lulizumab_pegol, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.